Exhibit 99.75
 
  THERATECHNOLOGIES ANNOUNCES FINANCIAL RESULTS AND CLOSES THE FIRST
QUARTER IN A STRONG FINANCIAL POSITION
 
    
    $57 M liquidity position and lower R&D expenses
    
    New date set for FDA Advisory Committee meeting
    
    Results from the second Phase 3 trial published in the medical journal JAIDS
    
    Patents granted for tesamorelin in Brazil and Australia
 Montréal, Canada  March 23, 2010
   th
 Highlights
 New date for the FDA Advisory Committee meeting
   Results from the second Phase 3 trial published in the medical journal JAIDS
 Effects of Tesamorelin, a Growth Hormone-Releasing Factor, in HIV-Infected
Patients With Abdominal Fat Accumulation: A Randomized Placebo-Controlled Trial With a Safety
Extension
 Theratechnologies Inc.    




---



##### 



Patents granted for tesamorelin in Brazil and Australia
  MANAGEMENTS DISCUSSION AND ANALYSIS FOR THE FIRST QUARTER
 Revenues
   R&D Activities
  Other Expenses
     Net Results
  2




---



##### 



Quarterly Financial Information
 Goodwill and Intangible Assets
  2010
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2009
    
    
    
    
    
    
    
    
    
    
    2008Q1
    
    
    Q4
    
    
    Q3
    
    
    Q2
    
    
    Q1
    
    
    Q4
    
    
    Q3
    
    
    Q2Revenues
    
    $
    2,295
    
    
    $
    2,246
    
    
    $
    13,148
    
    
    $
    2,317
    
    
    $
    2,009
    
    
    $
    616
    
    
    $
    710
    
    
    $
    716Net (loss)
earnings
    
    $
    (4,267
    )
    
    $
    (4,698
    )
    
    $
    5,824
    
    
    $
    (5,430
    )
    
    $
    (10,754
    )
    
    $
    (15,145
    )
    
    $
    (11,220
    )
    
    $
    (11,382
    )Basic and
diluted
(loss)
earnings
per share
    
    $
    (0.07
    )
    
    $
    (0.08
    )
    
    $
    0.10
    
    
    $
    (0.09
    )
    
    $
    (0.18
    )
    
    $
    (0.26
    )
    
    $
    (0.19
    )
    
    $
    (0.20
    )
  Financial Position
   New Accounting Policies
    Phase One: Diagnostic Phase
 3




---



##### 



Phase Two: Detailed Analysis 
 Phase Three: Design 
 Phase Four: Implementation 
 Outstanding Share Data
  Contractual Obligations
  Economic and Industry Factors
  About Theratechnologies
  Additional Information about Theratechnologies
 www.theratech.com www.sedar.com
 Forward-Looking Information
  4




---



##### 



www.sedar.com.
 Information:    communications@theratech.com
 ltanguay@theratech.com
 5




---



##### 



ANNEX A
 Non-GAAP measures
  Definition and reconciliation of non-GAAP measures
  First Quarter(Thousands of dollars)
    
    2010
    
    2009Adjusted net lossNet loss, per the financial statements
    
    $
    (4,267
    )
    
    $
    (10,754
    )Adjustments:Revenues associated with a collaboration and license agreement
(note 6 to the consolidated financial statements)
    
    $
    (1,711
    )
    
    $
    (1,426
    )Fees associated with collaboration and license agreement
    
    
    
    
    
    $
    4,269Adjusted net loss
    
    $
    (5,978
    )
    
    $
    (7,911
    )
 First Quarter2010
    
    2009Adjusted burn rate before changes in operating assets and liabilitiesBurn rate before changes in operating assets and liabilities, per the
financial statements
    
    $
    (3,861
    )
    
    $
    (10,412
    )Adjustments:Revenues associated with a collaboration and license agreement
(note 6 to the consolidated financial statements)
    
    $
    (1,711
    )
    
    $
    (1,426
    )Fees associated with collaboration and license agreement
    
    
    
    
    
    $
    4,269Adjusted burn rate before changes in operating assets and liabilities
    
    $
    (5,572
    )
    
    $
    (7,569
    )
 6